undamentalytics Newsletter
Sign in

Aquestive Therapeutics, Inc. cash flow statement

In fiscal 2025, Aquestive Therapeutics, Inc.'s operations generated −$52.4m of cash; it spent $562,000 on capital projects, leaving free cash flow of −$53.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations6−13−60−45−33−10−6−36−52−45
Depreciation and amortisation4333321111
Stock-based pay03077743789
Capital spending2211111011
Free cash flow4−15−61−46−34−11−7−36−53−46
Free cash flow after stock pay4−45−68−53−41−15−10−43−61−55

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AQST vs AYTUAQST vs BFRIAQST vs DERMAQST vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aquestive Therapeutics, Inc.